Related Post
- Micron Biomedical Extends Series A Financing to 33+ Million to Accelerate Commercialization of Needle-Free Therapeutics and Vaccines - January 17th, 2025
- Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale - January 17th, 2025
- Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland... - January 17th, 2025
- Avicanna Announces Scientific and Medical Affairs Collaboration with Vectura Fertin Pharma - January 17th, 2025
- Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema - January 17th, 2025
- Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis - January 17th, 2025
- Nusano and Atley Solutions in Collaboration to Accelerate Astatine-211 Development - January 17th, 2025
- United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer - January 17th, 2025
- Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones - January 17th, 2025
- Autoimmunity BioSolutions to Present at the 2025 Sequire Investor Summit in Puerto Rico - January 17th, 2025
- Boehringer provides update on iclepertin Phase III program in schizophrenia - January 17th, 2025
- Virbac: Strong annual revenue growth of +13.6% supported by dynamic organic growth (+7.5%) and the strategic contribution of our acquisitions (+6.1%) - January 17th, 2025
- Vaxil Bio Proposed Reverse Takeover With Green Date Terminated - January 17th, 2025
- Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an... - January 17th, 2025
- Scorpius Holdings Announces Reverse Stock Split - January 17th, 2025
- Codexis Appoints Christos Richards to Board of Directors - January 17th, 2025
- Illuccix® Receives European Approval - January 17th, 2025
- ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses - January 17th, 2025
- ProstaVive: Introducing ProstaVive as the New Standard of Prostate Support in 2025 - January 17th, 2025
- Junshi Biosciences Announces Toripalimab’s Approval in Australia - January 17th, 2025
- Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones - January 13th, 2025
- Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement - January 13th, 2025
- 4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway - January 13th, 2025
- Nusano Announces Isotope Availability - January 13th, 2025
- Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference - January 13th, 2025
- Pulmocide Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference - January 13th, 2025
- 4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path - January 13th, 2025
- Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160... - January 13th, 2025
- Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine - January 13th, 2025
- Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook - January 13th, 2025
- Mereo BioPharma Provides Update on Lead Clinical Programs - January 13th, 2025
- Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference - January 13th, 2025
- Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities - January 13th, 2025
- Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference - January 13th, 2025
- scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results - January 11th, 2025
- Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update - January 11th, 2025
- RESTEM Provides Corporate Update and Announces Key Business Objectives for 2025 - January 11th, 2025
- NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-Cell Lymphoma - January 11th, 2025
- Totus Medicines Announces Successful Completion of a Phase 1 Dose-Escalation Study and Initiation of an Expansion Trial Evaluating TOS-358, a Covalent... - January 11th, 2025
- NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers - January 11th, 2025
- InflammX Therapeutics Announces Option Agreement with Bausch + Lomb - January 11th, 2025
- LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - January 11th, 2025
- Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States - January 11th, 2025
- Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors - January 11th, 2025
- Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock - January 11th, 2025
- ADARx Pharmaceuticals to Present at the J.P. Morgan 43ʳᵈ Annual Healthcare Conference - January 11th, 2025
- Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in... - January 11th, 2025
- HMNC Brain Health Completes Patient Randomization for Phase 2b OLIVE Trial for Major Depressive Disorder - January 11th, 2025
- Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025 - January 11th, 2025
- Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs - January 11th, 2025
- Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities - January 11th, 2025
- Virbac : Declaration of the number of shares and voti - January 11th, 2025
- Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock - January 11th, 2025
- Matinas BioPharma Receives NYSE Noncompliance Notice - January 11th, 2025
- Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates - January 9th, 2025
- Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy - January 9th, 2025
- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - January 9th, 2025
- Ribometrix Strengthens Leadership, Appoints William S. Marshall, Ph.D., as Chief Executive Officer and Katie Warner, Ph.D., as Chief Scientific... - January 9th, 2025
- Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones - January 9th, 2025
- Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - January 9th, 2025
- TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - January 9th, 2025
- ElevateBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 9th, 2025
- RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 9th, 2025
- Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including... - January 9th, 2025
- Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential - January 9th, 2025
- Ori Biotech Expands Team to Advance IRO Commercialization and Industry Partnerships - January 9th, 2025
- IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as... - January 9th, 2025
- Alkeus Pharmaceuticals Announces New Positive Interim TEASE-3 Study Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage... - January 9th, 2025
- Biosphere Launches UV Bioreactor to Transform Industrial Fermentation - January 9th, 2025
- FYR Appoints Chris Howlett to its Board of Directors - January 9th, 2025
- Inmagene Reports Positive Topline Results of IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody with an Extended Half-Life, for the Treatment of... - January 9th, 2025
- CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - January 9th, 2025
- BioLizard Welcomes Arjan van Manen as Commercial Director and Announces Presence at JPM Week in San Francisco - January 9th, 2025
- Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference - January 9th, 2025
- ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease - January 7th, 2025
- Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update - January 7th, 2025
- Oncocyte Expands Market Opportunity for VitaGraft™ Kidney - January 7th, 2025
- Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
Recent Comments